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Abstract
CYP2D6 substrates are among the most highly prescribed medications in teenagers and also commonly associated with serious adverse events. To investigate the
relative contributions of genetic variation, growth, and development on CYP2D6
activity during puberty, healthy children and adolescents 7–15 years of age at
enrollment participated in a longitudinal phenotyping study involving administration of 0.3 mg/kg dextromethorphan (DM) and 4-h urine collection every
6 months for 3 years (7 total visits). At each visit, height, weight, and sexual maturity were recorded, and CYP2D6 activity was determined as the urinary molar
ratio of DM to its metabolite dextrorphan (DX). A total of 188 participants completed at least one visit, and 102 completed all seven study visits. Following univariate analysis, only CYP2D6 activity score (p < 0.001), urinary pH (p < 0.001),
weight (p = 0.018), and attention-deficit/hyperactivity disorder (ADHD) diagnosis (p < 0.001) were significantly correlated with log(DM/DX). Results of linear
mixed model analysis with random intercept, random slope covariance structure
revealed that CYP2D6 activity score had the strongest effect on log(DM/DX), with
model-estimated average log(DM/DX) being 3.8 SDs higher for poor metabolizers
than for patients with activity score 3. A moderate effect on log(DM/DX) was observed for sex, and smaller effects were observed for ADHD diagnosis and urinary
pH. The log(DM/DX) did not change meaningfully with age or pubertal development. CYP2D6 genotype remains the single, largest determinant of variability in
CYP2D6 activity during puberty. Incorporation of genotype-based dosing guidelines should be considered for CYP2D6 substrates given the prevalent use of these
agents in this pediatric age group.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
Several CYP2D6 substrates are used in the management of neurodevelopmental,
behavioral, and psychiatric disorders in children and adolescents, often off-label,
for indications that often differ from the adult conditions for which the medications originally were developed. Therefore, little information is available to guide
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dosing in pediatric patients, and even less regarding the influence of growth and
development on the processes influencing drug disposition and response.
WHAT QUESTION DID THIS STUDY ADDRESS?
What is the relative contribution of genetic variation and the processes of growth
and development on variability in CYP2D6 activity during puberty?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
CYP2D6 genotype remains the single, largest biological determinant of variability of CYP2D6 activity during puberty. Effects of factors associated with growth
and sexual maturation are small and have limited ability to explain variability in
CYP2D6 activity.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR
TRANSLATIONAL SCIENCE?
Incorporation of genotype-based dosing guidelines should be considered for
CYP2D6 substrates, especially given the prevalent use of antipsychotic and antidepressant medications in children and adolescents. A challenge for the future
remains to build on, and extend the accumulating database describing the relative contribution of ontogeny and genetic variation to observed variability in drug
disposition and response across the continuum from birth to adulthood.

I N T RO DU CT ION
The treatment of neurodevelopmental, behavioral, and
psychiatric disorders in children, such as attention-
deficit/hyperactivity disorder (ADHD), autism spectrum
disorder (ASD), and mood disorders, represents a critically important opportunity to optimize the use of medications through precision therapeutics. ASD, for example,
has a relatively high prevalence (2018 data) of 23 per 1000
(or 1 in 44) among 8-year-old children.1 Medications used
in the treatment of children with ASD primarily target
symptoms of irritability, aggression, and anxiety, with
the use of antipsychotic medications, such as risperidone,
aripiprazole, and quetiapine,2 and antidepressant medications, such as fluoxetine and sertraline. For many of these
patients, dose adjustment and optimization rely on interpretation of behavioral response to assess efficacy and
tolerance.
CYP2D6 pharmacogenetics has considerable potential to impact precision therapeutics in children,3,4
and guidelines for CYP2D6 genotype-dependent dose
adjustments are becoming available.5 Available data
indicate that CYP2D6 substrates risperidone, fluoxetine, aripiprazole, amitriptyline, and haloperidol,6 are
among the most highly prescribed central nervous system (CNS)-acting medications in children.7 A survey of
antipsychotics used in Medicaid-insured children and
adolescents revealed that among youth who used a single atypical antipsychotic agent (n = 8053), the top three
agents were risperidone (55.5%), aripiprazole (31.7%), and
quetiapine (20.6%).8 The majority of antidepressant and

antipsychotic use in children and adolescents is off-label.9
The primary indication for antipsychotics in children is
irritability and aggression in neurodevelopmental disorders compared to psychosis in adults. The limited data
from pediatric clinical trials have important safety implications as well. In an analysis of serious adverse events
in children aged 0–17 years reported to the US Food and
Drug Administration (FDA) from 2008–2012, 41% of all
reports were accounted for by a total of 15 drugs, including several CYP2D6 substrates associated with psychiatric
side effects (i.e., aripiprazole, quetiapine, risperidone, and
atomoxetine).10 Available data suggest that selective serotonin reuptake inhibitor adverse drug reactions (e.g., agitation, restlessness, hyperactivity, and irritability) are two
to three times more prevalent in younger children than in
adolescents, and lowest in adults.11 Given that side effect
profiles may be age-dependent and differ between children and adults, the need for a better understanding of the
dose→exposure→response relationship for these medications in children is becoming increasingly apparent.
It has been proposed that children as young as 4 years of
age can be considered as small adults such that scaling of
pharmacokinetic parameters based on body weight alone
allows available adult data to inform pediatric dosing.12
However, the premise that maturational processes may be
sufficiently complete to infer drug disposition in children
and adolescents from adult data does not necessarily apply
to expression and function of drug targets. Furthermore,
the process of dose selection for use in a pediatric clinical
trial intended to generate population data for regulatory
purposes is different than the clinical situation faced by
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a pediatrician who must adequately manage the disorder
for the specific child for whom a medication has been prescribed. In this context, individual children are NOT small
average adults, and the challenge is to identify factors that
make each child unique, and to develop dosing strategies
that take these unique characteristics into consideration.
The impact of developmental changes in the processes
governing drug absorption, distribution, metabolism, and
excretion from birth through adolescence on drug dosing in children is well-recognized,13 and new knowledge
continues to accumulate.14,15 In the current investigation,
we conducted a longitudinal phenotyping study to assess
the relative contribution of genetic variation and the processes of growth and development to observed variability
in CYP2D6 activity during puberty.

M ET H O DS
Study participants
This study was open to healthy children and adolescents
7–15 years of age, boys or girls, of any racial or ethnic background. A subset of participants were pediatric patients
meeting the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV) criteria for a primary
diagnosis of ADHD or attention-deficit disorder (ADD) to
facilitate a substudy assessing the effect of CYP2D6 genotype on the atomoxetine dose–exposure relationship.16
Participants were recruited through notices posted in the
Developmental and Behavioral Health Clinics and directly
by providers in those clinics. Study enrollment opportunity was also shared system-wide through a staff-facing
website at Children's Mercy Kansas City, Kansas City, MO.
Participants were deemed to be otherwise healthy as determined by physical and laboratory examination, including
laboratory assessment of hepatic, renal, and hematopoietic
function. Exclusion criteria included: an adverse reaction
to dextromethorphan (DM); historical or physical evidence
of any disorder associated with swallowing or gastrointestinal function that may influence absorption and/or gastric emptying, such as reflux, inflammatory bowel disease,
or Crohn's disease; historical or physical evidence of neurological disease (excluding simple febrile seizures and/or
ADHD); patients with known serious structural cardiac
abnormalities, cardiomyopathy, serious heart rhythm
abnormalities, or other serious cardiac problem; concurrent therapy with medications known to inhibit CYP2D6
(listed in Supplementary Methods). Additional exclusion criteria included treatment within the past 2 months
with paroxetine or fluoxetine, or the past 6 months with
terbinafine; clinically significant abnormal safety laboratory values as determined by the treating physician; and

pregnancy. If during the 3-year longitudinal phase of the
study, participants were prescribed medications known
to be CYP2D6 inhibitors, they were allowed to continue
in the study; the dose and start date of these medications
were recorded and the effect of the inhibitor on CYP2D6
activity was assessed, but the data points were excluded
from the ontogeny and genotype–phenotype correlation
analysis, as described in more detail below. The study
was approved by the University of Missouri-Kansas City
Pediatric Institutional Review Board at Children's Mercy
Hospitals and Clinics, Kansas City, MO, and registered
as study NCT01118858 at ClinicalTrials.gov. Written, informed parental permission and child/adolescent assent
was obtained for each participant.

Study protocol and procedures
During the pre-study screening visit, prospective participants (and their parents) were provided with a description of the proposed study, their questions were
answered, and they were given a copy of the permission/assent form to review and sign. After review of
participants' medical history and use of medications,
including any non-prescription and herbal remedies,
all participants underwent a complete physical examination, including vital signs (blood pressure, heart rate,
respiration rate, and temperature), height, and weight.
Body mass index (BMI) was calculated from height and
weight, and z-scores/percentiles for height, weight, and
BMI for age and sex were determined using Centers for
Disease Control and Prevention (CDC) growth charts
and an internally developed program.17 Pubertal development was assessed by Tanner stage, breast development was assessed by both visual inspection and
palpation, pubic hair was assessed by visual inspection,
and testicular volume was measured by direct comparison to orchidometer beads. All Tanner staging was
conducted by pediatric subspecialists and scored (stages
1 through 5) based on the methods of Marshall and
Tanner18,19 as described in Zitelli and Davis.20 For male
pubic hair development, a Tanner score of 6 is possible
and scores of 6 were included with the Tanner 5 group.
Blood was drawn for serum chemistries, liver function
tests and a hematology panel, and CYP2D6 genotyping.
A urine pregnancy test was performed for any girls of
childbearing potential.

Dextromethorphan phenotyping protocol
Participants were admitted to the study unit the morning after an overnight fast (only water was permitted).
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At each study visit, the medical history and use of
medications were reviewed and recorded, and all participants underwent a physical examination and an assessment of pubertal development by Tanner stage, as
described above. Prior to DM administration, the participants completely emptied their bladders and provided
a blank urine sample. A single 0.3 mg/kg dose of DM
as Robitussin Cough (7.5 mg/5 ml; alcohol-free, fruit
punch flavor), as used in previous studies, 21,22 was administered orally. All urine produced over the 4-h study
period was collected, pH measured using an Accumet
model AB15 pH meter (Fisher Scientific, Pittsburgh,
PA), and an aliquot retained for analysis of DM and its
three metabolites. One hour after dosing, participants
were provided with a small meal selected from the
standard hospital menu. If participants were suffering
from flu-like symptoms around the time of the scheduled study visit, the visit was re-scheduled for 1–2 weeks
later. This phenotyping protocol was conducted as described above, every 6 months for a total of seven phenotyping visits over 3 years.

CYP2D6 genotyping
CYP2D6 genotyping was conducted as described in detail elsewhere.23–27 Details of genotyping strategy and
assays24–29 are provided in Supplementary Methods
and Table S1. Alleles were defined according to the
Pharmacogene Variation Consortium (PharmVar) at
https://www.pharmvar.org/gene/CYP2D6.30
CYP2D6 genotype data were translated into predicted
phenotypes based on “activity score” (AS), a simplified system to infer predicted phenotype from diplotype
calls.29,31 Genotypes were translated into predicted phenotypes as recommended by the Clinical Pharmacogenetics
Implementation Consortium (CPIC) and Dutch
Pharmacogenetics Working Group (DPWG).32 Normal
function alleles (CYP2D6*1, *2, *35, etc.) were assigned a
value of “1,” decreased function alleles a value of “0.25”
(*10) or “0.5” (*9, *17, and *29), and no function alleles
(*3, *4, *5, *6, etc.) a value of “0”; for duplications/multiplication events, the value was multiplied by the number
of copies detected (e.g., CYP2D6*2 × 2 = 1 × 2 = “2”). The
AS for an individual study participant was assigned as the
sum of the scores for each allele, with poor metabolizers
(PMs) defined by an AS of “0” and ultrarapid metabolizers (UMs) defined by an activity score ≥2.25. Participants
with an AS of 0.25 (n = 1), 0.75 (n = 1), and 1.25 (n = 3)
were grouped with the next higher AS group (0.5, 1, and
1.5, respectively) for analyses. CYP2D6 genotypes and assigned phenotypes for study participants are provided in
Table S2.
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Phenotyping analysis
Urinary concentrations of DM and its metabolites dextrorphan (DX), 3-methoxymorphinan, and 3-hydroxymorphinan
were quantified by high-performance liquid chromatography with fluorescence detection, as described previously.22
Details are provided in Supplementary Methods.

Statistical analysis
Normality of variable distribution was assessed by visual
inspection of frequency histograms and normal quantile
plots. Normally distributed continuous variables are summarized with mean ± SD, and non-normally distributed
variables are summarized with median and interquartile
range. The urinary DM/DX ratio was log-transformed
for analyses (log(DM/DX)). An initial univariate analysis
was conducted to explore the effect sizes and explanatory
power of the demographic, developmental, physiological, and genetic variables of interest on log(DM/DX); the
relationship between log(DM/DX) and continuous variables was estimated by linear regression, whereas analysis of variance (ANOVA) followed by post hoc analysis
using Tukey's Honestly Significant Difference was used
for nominal and categorical variables. These preliminary
analyses were primarily for the purposes of visualization
and were not adjusted for other explanatory variables or
clustering of visits within participants. Assessments of
variable distribution, linear regression, and ANOVA were
conducted using JMP Pro 14 (SAS) with a nominal threshold of significance set at p < 0.05.
Linear mixed modeling was conducted to assess the
effect of age on log-transformed urinary DM/DX ratio
(log(DM/DX)) with adjustment for dependence of repeated observations within participant. Linear mixed
models were fit in SAS using the Mixed Procedure, with
age at study visit, race, sex, ADHD diagnosis, CYP2D6
AS, and urinary pH included as explanatory variables.
An age X sex interaction was included in the model as
pubertal growth spurts and sexual maturation occur earlier in girls than in boys. To choose a covariance structure, the model was fit three times: once with a random
patient intercept and first-order autoregressive (AR (1))
structure specified, once with a random patient intercept
and random patient age slope, and once with a random
patient intercept, random patient slope, and AR (1) structure specified. Models were fit with maximum likelihood
to allow comparison of covariance structures using the
Bayesian Information Criterion (BIC), a likelihood-based
measure of model fit.
To evaluate effects on log(DM/DX) of surrogates
of age associated with growth (height and weight) or

17528062, 2022, 10, Downloaded from https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.13380, Wiley Online Library on [21/10/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

LONGITUDINAL STUDY OF CYP2D6 ACTIVITY IN PUBERTY

|

  

development (Tanner scores for pubic hair and testicular size/breast development), the model described above
was re-fit with each surrogate substituted for age. For
example, the height model included height and a height
X sex interaction in place of age and an age X sex interaction, and a random patient height (rather than age)
slope. Although height and weight are correlated, each
was substituted for age in the model as there is a limit
as to how tall an individual will grow, but there is no
limit on how heavy they may become. Similarly, changes
in pubic hair and increases in testicular size for boys or
breast development in girls demonstrate different developmental trajectories,18,19 and were also assessed
individually. As with the age model, each of the four
surrogate models was fit three times, once for each of
the three covariance structures.

RES ULT S
Demographic characteristics of the study
population
A total of 188 children and adolescents, representing 116
families (41 families with 2 siblings, 10 families with 3 siblings, and 4 families with 4 siblings) completed at least one
study day. Over the 3-year study period, a total of 1115
study days were completed, and 102 participants completed all seven study visits. The number of participants
completing each study visit decreased at each visit. Loss
to follow-up was primarily due to an inability to contact
the family to schedule the following visit. No participants
discontinued the study due to an adverse reaction related
to DM administration.
Twelve postdose urine samples were excluded from
the statistical analysis. Five samples were from a participant who was enrolled while taking a medication that
was not included in the list of exclusions, in part, due to
confusion between “bupropion,” a CYP2D6 inhibitor, and
“buspirone,” a non-CYP2D6 inhibitor. This individual had
urinary log(DM/DX) values concordant with genotype, albeit at the low end of the distribution for AS of 1.5, and
five study visits were completed before the interaction was
recognized. One urine sample from one participant was
excluded due to an interfering peak, present in both the
pre- and postdose visit four urine samples, that precluded
accurate quantitation of DM in the postdose sample. Two
participants reported fluoxetine as a concurrent medication at visits six and seven resulting in the exclusion of
these samples, accounting for 10 of the excluded samples.
For the remaining two excluded samples, fluoxetine use
was not reported for either participant at visit five, but the
urinary DM/DX ratio values for both participants were

LEEDER et al.

similar to the values obtained at visits six and seven, and
markedly different from the values obtained at visits one
through four (see footnote a in Table 1). As neither the
participant or parent reported fluoxetine use at that visit,
it was not possible to determine with certainty whether
concurrent fluoxetine was present, or not. Therefore, the
analysis was conduct with (n = 1105 evaluable samples)
or without (n = 1103 evaluable samples) the visit five
samples for these participants across the seven visits, with
714 samples contributed by the 102 participants who completed all seven study visits.
The number of participants completing each study visit
and their demographic characteristics are presented in
Table 1. Participants were primarily of European descent
(47%) or African American (41%), 60% were boys, and
~40% of the cohort had a diagnosis of ADHD/ADD. There
were no significant changes in any of these characteristics
across the study visits due to dropouts, nor in the pattern
of medication use within the ADHD/ADD subgroup.
At the first study visit, the mean age was 11.2 ± 2.5 years.
For those participants completing all visits (n = 102),
height increased by 16.8 ± 6.4 cm. Inspection of the distribution of height revealed a subset of 14 participants
(5 boys and 9 girls) who grew significantly less (3.5 ± 2.1 cm,
range: 0–7.7 cm) than the majority of the cohort
(18.9 ± 3.8 cm, range: 11.1–26.7 cm; p < 0.001; Figure S1A),
consistent with near complete maturity at the start of the
study. Twelve of 14 participants were Tanner stage 4 or 5
at visit one, indicating that growth and development was
nearly complete for this cohort. This subset was significantly older (13.7 ± 0.8 vs. 10.0 ± 1.9 years, p < 0.001) and
gained less weight (9.5 ± 7.4 vs. 17.9 ± 8.4 kg, p < 0.001)
than the other participants. Overall, weight increased by
16.7 ± 8.7 kg for the entire study group; for three participants, weight increased more than 40 kg (Figure S1B).
From a developmental perspective, the average
Tanner score increased from ~2.4–3.7 over the 3-year
study period (p < 0.001). The distribution of Tanner
scores at each visit is presented separately for pubic
hair and for breast development (girls) or testicular
size (boys) in Table 1. Maturation of the cohort over the
study period is presented in Figure 1a,b. Hierarchical
clustering of the Tanner stage data for breast development/testicular size and pubic hair for the 102 participants completing all 7 study days revealed two distinct
clusters that could be broadly defined as “not maturing”
(n = 32) or “maturing/fully matured” (n = 70). The “not
maturing group” was defined by Tanner stage (generally
stage 1 for at least the first four visits and no progression
beyond stage 3, except at the final visit) and younger
age at entry into the study compared to the maturing/
fully matured group. The younger, non-maturing group
tended to have a greater height increase (18.3 ± 3.0 vs.
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115 (61.2)

Boys (%)

15 (8.0)

5 (2.7)

Mixed EA-AA (%)

Other (%)

Height (cm)

2.37

Pubic hair Tanner stagef

6 (3.5)

160 (60.6)

6 (3.2)

NM (%)

54 (31.2)
6 (3.5)

46 (24.5)

56 (29.8)

58 (30.9)

6 (3.2)

6.71 ± 0.57

0.75–1

1.25–1.5

2

>2.25

Urinary pH

6.45 ± 0.60

6 (3.6)

52 (31.5)

46 (27.9)

44 (26.7)

10 (6.1)

7 (4.2)

6 (3.6)

98 (59.4)

54 (32.7)

7 (4.3)

2.79

2.78

79.0 (52.1, 92.9)

75.8 (48.7, 94.4)

55.8 ± 30.0

20.2 (17.8, 24.2)

47.5 (34.3, 64.5)

152.1 ± 15.2

5 (3.0)

14 (8.5)

68 (41.2)

78 (47.3)

102 (61.8)

12.1 ± 2.4

165

Visit 3

6.55 ± 0.58

5 (3.3)

51 (33.8)

37 (24.5)

40 (26.5)

8 (5.3)

10 (6.6)

5 (3.3)

88 (52.3)

48 (31.8)

10 (6.6)

2.91

2.99

79.9 (48.3, 94.0)

77.0 (45.0, 94.2)

54.0 ± 29.8

20.9 (17.6, 25.1)

49.2 (36.5, 65.0)

153.4 ± 14.8

4 (2.7)

15 (9.9)

59 (39.1)

73 (48.3)

95 (62.9)

12.5 ± 2.4

151

Visit 4

6.69 ± 0.54

5 (3.3)

51 (33.8)

42 (27.8)

35 (23.2)

9 (6.0)

9 (6.0)

5 (3.3)

90.2 (60.9)

45 (29.8)

9 (6.0)

3.31

3.36

78.0 (53.5, 93.3)

76.1 (52.6, 94.7)

55.1 ± 29.7

21.5 (18.6, 25.1)

53.9 (40.0, 69.1)

156.5 ± 13.8

2 (1.3)

13 (8.6)

60 (39.7)

76 (50.3)

92 (60.9)

13.1 ± 2.5

151

Visit 5

6.77 ± 0.59

5 (3.5)

45 (31.3)

42 (29.2)

38 (26.4)

7 (4.8)

7 (4.8)

5 (3.5)

86 (59.7)

46 (31.9)

7 (4.9)

3.45

3.51

78.2 (55.0, 92.6)

78.6 (51.2, 93.9)

55.9 ± 28.7

21.8 (18.8, 24.5)

55.7 (41.9, 69.8)

158.6 ± 13.5

3 (2.1)

11 (7.6)

62 (43.1)

68 (47.2)

89 (61.8)

13.4 ± 2.5

144

Visit 6

6.71 ± 0.62

3 (2.3)

45 (34.4)

37 (28.2)

35 (26.7)

6 (4.6)

5 (3.8)

3 (2.3)

80 (61.1)

43 (32.8)

5 (3.8)

3.66

3.73

77.2 (53.7, 93.8)

78.2 (47.4, 95.0)

56.9 ± 30.2

21.4 (18.7, 24.4)

55.7 (43.8, 68.6)

160.2 ± 13.1

3 (2.3)

14 (10.7)

54 (41.2)

60 (45.8)

81 (61.8)

13.6 ± 2.21

131

Visit 7
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6.37 ± 0.60

45 (26.0)

46 (26.6)

12 (6.9)

12 (6.4)

0.25–0.5

10 (5.8)

10 (5.3)

0

CYP2D6 AS

UM (%)

99 (57.2)

58 (30.9)

IM (%)

58 (33.5)

10 (5.3)

10 (5.8)

2.57

2.61

76.4 (51.9, 92.7)

76.2 (45.0, 93.8)

55.8 ± 29.6

19.8 (17.1, 23.6)

43.9 (32.1, 60.4)

149.1 ± 15.5

5 (2.9)

14 (8.1)

75 (43.3)

79 (45.7)

105 (60.7)

11.6 ± 2.4

173

Visit 2

PM (%)

CYP2D6 genotypeg

2.39

77.7 (53.6, 92.0)

74.4 (43.9, 91.8)

55.6 ± 29.8

19.2 (17.1, 23.0)

41.6 (30.7, 57.9)

Testicular/breast Tanner
stagee

BMI percentile

c,d

Weight percentile

c,d

Height percentiled

BMI (kg/m )

2 c

Weight (kg)c

146.8 ± 15.9

80 (42.5)

African American (%)

b

88 (46.8)

European ancestry (%)

Race

188

11.2 ± 2.5

Age (year)b

Visit 1

Characteristics of participants at each individual study visit included in the analysis (n = 1103 total visitsa)

n

TABLE 1
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h
Stimulant medication use for ADHD patients only, expressed as number of participants prescribed any stimulant (amphetamine-related or methylphenidate formulation)/number of ADHD participants (and as a
percentage).

Genotype-based predicted phenotype updated according to the Clinical Pharmacogenetics Implementation Consortium guidelines: poor metabolizer (PM), activity score = 0; intermediate metabolizer (IM),
0 < AS < 1.25; normal metabolizer (NM), 1.25 ≤ AS ≤ 2.25; ultrarapid metabolizer (UM), AS > 2.25. Phenotype was assigned as described in Table S2.

Percentile for age and sex based on CDC growth charts.

g

f

Tanner staging for testicular size (boys) and breast development (girls); weighted average score followed by sex distribution for each stage.

Tanner staging for pubic hair; weighted average score followed by sex distribution for each stage (Tanner score of 6 for pubic hair is possible for males only; a score of 6 was reported together with scores of 5).

e

d

Mean ± SD.

Median (interquartile range); comparison using Wilcoxon/Kruskal–Wallis rank sum test.

c

b

The visit 4 sample from participant K198 was not included in the dataset due to the presence of an interfering peak that precluded accurate quantitation of DM; the interfering peak was also present in the pre-dose
sample. For participants K196 and K198, fluoxetine was reported as a concurrent medication at study visits 6 and 7; thus, samples from those visits were excluded from statistical analysis. Although fluoxetine was not
reported at the study 5 visits, the urinary DM/DX ratio values at that visit for each participant (DM/DX = 2.000 for K196 and 0.381 for K198) were similar to the values obtained at visits 6 and 7 (0.335 and 0.597 for
K196; 0.869 and 0.314 for K198), and markedly different from the values obtained at visits 1 to 4 (0.028–0.043 for K196, and 0.010–0.021 for K198). As described in Results, the linear mixed model analysis was conducted
with and without the visit 5 data for these two subjects.

a

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; BMI, body mass index; CDC, Centers for Disease Control and Prevention; DM, dextromethorphan; DX, dextrorphan; EA-AA, European American–
African American.

19/49 (38.8)
25/54 (46.3)
42/67 (62.7)

ADHD (%)

h

Stimulant – Any (%)

55/73 (75.3)

38/65 (58.5)

35/59 (59.3)

28/57 (49.1)

49 (37.4)
54 (37.5)
67 (38.7)
73 (38.8)

65 (39.4)

59 (39.1)

57 (37.7)

Visit 7
Visit 5
Visit 4
Visit 2
Visit 1

Visit 3
(Continued)
TABLE 1
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15.5 ± 7.2 cm, p = 0.106) and comparable weight gain
(16.1 ± 7.4 vs. 17.3 ± 9.3 kg, p = 0.349) over the 3-year
period, clearly differentiating between growth and development within this group.
Approximately 5% of the cohort (range: 3.8%–6.6%
per visit) were CYP2D6 PMs, and 3.3% were UMs (range:
2.3%–3.6% per visit). The distribution of genotypes classified as PM, intermediate metabolizer, normal metabolizer,
and UM by AS did not vary markedly across study visits
(Table 1).

Univariate effects on CYP2D6 phenotype
(log(DM/DX))
The univariate effect of CYP2D6 AS, age, height, weight,
Tanner score (pubic hair and breast development/testicular size), ADHD status, and urine pH on log(DM/DX) for all
study visits (1103 total visits) was assessed. Only CYP2D6
AS (p < 0.001), urinary pH (p < 0.001), weight (p = 0.018),
and ADHD status (p < 0.001) were significant (p < 0.05
without adjustment for clustering of visits within participant). Compared to the effect of CYP2D6 AS (r2 = 0.716;
Figure 2) and urinary pH (slope = 0.428, r2 = 0.116;
Figure 3), the effect sizes for age (slope = 0.016, r2 = 0.003,
p = 0.063; Figure 4a) and weight (slope = 0.003, r2 = 0.005;
Figure 4b) were considerably smaller with limited explanatory power. The distribution of log(DM/DX) values across
Tanner stages for pubic hair and breast development/testicular size are presented in Figure 5a,b, respectively.
The effect of CYP2D6 AS was present at each study
visit (Figure S2), and was similar for African Americans
(p < 0.001) and those of European ancestry (p < 0.001), although only one African American participant was genotyped as a PM. The effects of genotype were similar in boys
and girls. Decreasing log(DM/DX) values with increasing
urine pH was observed for all AS groups except AS greater
than 2.25 (Figure 3), whereas the effects of age and weight
were uniformly small with limited explanatory power
within AS groups (Figure 4a,b, respectively). The differences in log(DM/DX) between patients with ADHD and
non-ADHD patients were limited to PMs and the AS = 2
group (data not shown).

Linear mixed model analysis
The random intercept, random slope covariance structure
was selected as the most appropriate covariance structure
based on the lowest (best) BIC score across all five analyses (age, height, weight, Tanner stage for breast development/testicular size, and Tanner stage for pubic hair stage;
see Table S3). Among the five models evaluated with this
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F I G U R E 1 Mosaic plots describing the maturation of study participants over the 3-year study period for all participants and the subset
of participants that completed all seven visits. Participants were assessed by Tanner staging for breast development and pubic hair for
girls, testicular size and pubic hair for boys, and are presented for all study visits by 188 participants (panel a) and the 714 visits for the 102
participants completing all seven visits (panel b). The proportion of participants at a particular Tanner stage at each study visit is represented
by shading gradation from white (stage 1), light gray (stage 2), medium gray (stage 3), dark gray (stage 4), to black (stage 5). Tanner stage 6
for pubic hair in boys were included in the Tanner stage 5 group. The width of the columns of the mosaic plot is proportional to the number
of participants at each visit; in panel a, the width of the columns decreases as the number of participants decreases from 188 at visits 1–131
at visit 7, whereas the columns are equal in size for panel b as there were 102 participants for each study visit.

covariance structure, the age model had slightly better fit
than the surrogate models, and the regression coefficients
for the four surrogate models were almost identical to
those for the age model (Table 2).
The strongest effects on log(DM/DX) were observed
for CYP2D6 AS, with model-estimated average log(DM/
DX) being 3.8 SDs higher for PMs than for patients with
AS 3, adjusting for other explanatory variables (e.g., age,
developmental factors, race, sex, and urinary pH). A moderate effect was observed for sex, with girls averaging an

estimated 0.4 SDs lower than boys on log(DM/DX), and
smaller effects were observed for ADHD diagnosis and
urinary pH. There was little evidence that log(DM/DX)
changes meaningfully with age or pubertal development.

DISC USSION
Optimal use of medications in children requires consideration of several issues not commonly encountered in
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F I G U R E 2 Relationship between urinary log(DM/DX) ratio
and CYP2D6 genotype as expressed by activity score (AS). Data
from all seven study visits are presented together. All groups
were statistically significantly different by ANOVA followed by
Tukey's Honestly Significant Difference (p < 0.001; p = 0.014 for
AS = 2 vs. AS > 2.25); p values were not adjusted for clustering of
visits within participants. ANOVA, analysis of variance; DM/DX,
dextromethorphan/dextrorphan.

F I G U R E 4 Relationship between CYP2D6 activity expressed
as the log(DM/DX) ratio and age (panel a) or weight (panel b).
Data from all seven study visits are presented together. Data are
color-coded by CYP2D6 activity score (AS). Linear regression was
conducted for each AS group: 0 (red), 0.5 (yellow), 1 (green),
1.5 (turquoise), 2 (blue), and greater than or equal to 2.25
(black). Values for slope, coefficient of determination (r2) and
p values are presented in the inset of each panel; p values were
not adjusted for clustering of visits within participants. DM/DX,
dextromethorphan/dextrorphan; NS, not significant.

F I G U R E 3 Relationship between CYP2D6 activity expressed
as the log(DM/DX) ratio and urinary pH. Data from all seven study
visits are presented together. Data are color-coded by CYP2D6
activity score (AS). Linear regression was conducted for each AS
group: 0 (red), 0.5 (yellow), 1 (green), 1.5 (turquoise), 2 (blue), and
greater than or equal to 2.25 (black). Values for slope, coefficient of
determination (r2), and p values are presented in the inset; p values
were not adjusted for clustering of visits within participants. DM/
DX, dextromethorphan/dextrorphan; NS, not significant.

adults. Specifically, growth and development should be
considered in addition to genetic variation and environmental influences as factors contributing to variability in
drug disposition and response.

Given the prevalent use of CNS-acting medications in
adolescents, many of which are CYP2D6 substrates,2 we
conducted a longitudinal phenotyping study to assess factors contributing to variability in CYP2D6 activity during
puberty. Among the factors assessed, CYP2D6 genetic
variation (as reflected by activity score) had the greatest
influence on the log-transformed urinary DM/DX ratio. In
contrast, the effect of age, per se, or surrogates of age, such
as weight or height representing growth, or Tanner stages
representing sexual maturation were small and had limited explanatory power.
The effect of urinary pH on log(DM/DX) was first reported by Labbé et al.,33 who reported three-  to 20-fold
intra-individual variability in the urinary DM/DX ratio
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F I G U R E 5 Relationship between CYP2D6 activity expressed as
the log(DM/DX) ratio and Tanner score for pubic hair (panel a) and
for breast development in girls and testicular size in boys (panel b).
Data from all seven study visits are presented together. For pubic
hair, a Tanner score of 6 is possible for boys, but not girls, and all
scores of 6 were included in the Tanner score 5 group. Data are
color-coded by CYP2D6 activity score (AS): 0 (red), 0.5 (yellow),
1 (green), 1.5 (turquoise), 2 (blue), and greater than or equal to 2.25
(black). DM/DX, dextromethorphan/dextrorphan.

as a function of urinary pH and estimated that day-to-day
variation in urinary pH may explain between 20% and 80%
of the observed intra-individual variability in urinary DM/
DX ratios. Given that urinary pH can affect the assessment
of CYP2D6 phenotype using DM as a probe, Özdemir et al.
further assessed the sensitivity of urinary metabolite ratios for DM and two other CYP2D6 phenotyping probes to
changes in urinary pH produced by acidification and alkalinization with orally administered ammonium chloride
and sodium bicarbonate, respectively.34 Using this protocol, the urinary DM/DX ratio for 12 participants were
0.0017, 0.0120, and 0.0003 under control conditions (average urinary pH 6.5), acidification (pH 4.9), and alkalinization (pH 8.4), respectively—a 40-fold difference in urinary
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DM/DX ratio at the extremes of urinary pH generated by
the study conditions. As the individual urinary pH values
determined in our study (6.60 ± 0.60, range: 5.00–8.03) fell
within the range reported by Özdemir et al.,34 it is reasonable to expect that pH will have a similar influence on the
observed log(DM/DX) values. Therefore, variability in urinary pH can be expected to confound the assessment of
CYP2D6 activity and phenotype classification and obscure
subtle effects of other covariates on CYP2D6 activity in our
patient population. For the 102 participants completing all
seven visits, the difference between minimum and maximum pH value averaged 1.44 ± 0.47 units per participant
(range: 0.45–2.65), corresponding to a 27.5-fold range in
hydrogen ion concentrations. In our dataset of 1103 samples, urinary pH preferentially affected the observed DM
concentration (log[DM] vs. pH: slope = −0.407, r2 = 0.178,
p < 0.001) relative to DX (log[DX] vs. pH: slope = 0.021,
r2 < 0.001, p = 0.337, data not shown). Given that the effect of urinary pH may confound the magnitude of the
CYP2D6 genotype-dependent effect in individuals with
functional CYP2D6 activity, development of a correction
factor to minimize the influence of urinary pH on the estimation of CYP2D6 activity from urinary metabolite ratio
data would be valuable for further studies investigating
non-genetic sources of variability in CYP2D6 activity.
Beyond concerns regarding the potential for urinary
pH to confound data interpretation, it is reasonable to
consider whether CYP2D6 activity may be expected to
demonstrate growth-  or development-related changes
during puberty. Physical changes occurring during puberty in boys and girls are the result of rising levels
of testosterone and estradiol in response to rising concentrations of luteinizing hormone and follicle stimulating hormone secreted by the anterior pituitary. We
observed a moderate effect for sex, with girls averaging
an estimated 0.4 SDs lower log(DM/DX) values (higher
activity) than boys. In adults, differences in urinary
DM/DX ratios have been difficult to detect due to high
interindividual variability in urinary DM/DX ratios
and issues, such as the sample size required to detect
small effects. For example, studies involving larger
numbers of participants 33,35–37 have observed differences between males and females, whereas smaller
studies involving 10–12 participants of each gender38,39
did not. Thus, observed effects generally are small or
inconsistent such that the effect of gender is likely of
limited clinical relevance, especially given that the
urinary DM/DX ratio has been reported to vary up to
20-fold in the same individual assessed on multiple
occasions. 33,38,40
More relevant to the role of hormones in the physical changes associated with puberty, hormonal changes
occurring during the menstrual cycle or between oral
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0.0 (0.0, 0.1)

Age or surrogate variable X girls

0.2 (0.1, 0.3)

ADHD (patient vs. control)

0.9 (0.6, 1.2)

0.4 (0.1, 0.7)

1.5

2

−0.2 (−0.2, −0.2)

0.9 (0.6, 1.2)

<0.001

<0.001

−0.2 (−0.2, −0.2)

Reference

0.4 (0.1, 0.7)

1.0 (0.7, 1.4)

<0.001
0.009

3.8 (3.5, 4.2)
2.2 (1.8, 2.5)

<0.001

0.2 (0.1, 0.3)

0.0 (−0.1, 0.1)

0.2 (−0.1, 0.6)

0.0 (−0.1, 0.2)

0.1 (0.0, 0.2)

<0.001

<0.001

0.792

0.219

0.771

0.003

0.0 (−0.1, 0.0)
−1.3 (−2.3, −0.4)

<0.001

0.009

<0.001

<0.001

<0.001

<0.001

<0.001

0.768

0.173

0.630

0.002

0.006

0.013

p value

−0.2 (−0.2,
−0.2)

Reference

0.4 (0.1, 0.7)

0.9 (0.6, 1.2)

1.1 (0.8, 1.4)

2.2 (1.9, 2.6)

3.8 (3.5, 4.2)

0.2 (0.1, 0.3)

0.0 (−0.1, 0.1)

0.2 (−0.1, 0.5)

0.0 (−0.2, 0.2)

0.1 (0.0, 0.1)

−0.1 (−0.4, 0.2)

0.0 (−0.1, 0.0)

β (95% CI)

Weight (10 kg)

<0.001

0.007

<0.001

<0.001

<0.001

<0.001

<0.001

0.853

0.229

0.667

0.025

0.422

0.021

p value

−0.2 (−0.2,
−0.2)

Reference

0.4 (0.1, 0.7)

0.9 (0.6, 1.2)

1.1 (0.7, 1.4)

2.2 (1.8, 2.5)

3.8 (3.4, 4.2)

0.2 (0.1, 0.3)

0.0 (−0.1, 0.1)

0.2 (−0.1, 0.5)

0.0 (−0.2, 0.2)

0.1 (0.0, 0.1)

0.0 (−0.2, 0.2)

0.0 (−0.1, 0.0)

β (95% CI)

<0.001

0.010

<0.001

<0.001

<0.001

<0.001

<0.001

0.770

0.224

0.709

0.017

0.853

0.104

p value

Tanner stage: breast/
testicular size

0.009

<0.001

<0.001

<0.001

<0.001

<0.001

0.766

0.221

0.707

0.023

0.847

0.421

p value

−0.2 (−0.2, −0.2) <0.001

Reference

0.4 (0.1, 0.7)

0.9 (0.6, 1.2)

1.1 (0.8, 1.4)

2.2 (1.8, 2.5)

3.8 (3.4, 4.2)

0.2 (0.1, 0.3)

0.0 (−0.1, 0.1)

0.2 (−0.1, 0.5)

0.0 (−0.2, 0.2)

0.1 (0.0, 0.1)

0.0 (−0.2, 0.2)

0.0 (0.0, 0.0)

β (95% CI)

Tanner stage: pubic hair

Participants with an AS of 0.25 (n = 1), 0.75 (n = 1), and 1.25 (n = 3) were grouped with the next higher AS group (0.5, 1 and 1.5, respectively) for analyses.
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a

Abbreviations: AA, African American; ADHD, attention-deficit/hyperactivity disorder; AS, activity score; CI, confidence interval; DM/DX, dextromethorphan/dextrorphan ratio; EA, European Ancestry; EA_AA, mixed
European and African American ancestry.

Note: Log(DM/DX) and urinary pH were standardized for modeling. Values in bold are statistically significant at the p < 0.05 level.

Urinary pH

Reference

1.1 (0.8, 1.4)

1

3

3.8 (3.4, 4.2)

2.2 (1.8, 2.5)

0

0.5

AS

Referent

AA

a

0.2 (−0.1, 0.5)

0.0 (−0.1, 0.1)

Other

EA

0.0 (−0.2, 0.2)

EA_AA

Race

0.036

0.121

0.0 (0.0, 0.0)

−0.4 (−0.9, −0.1)

Base model

β (95% CI)

p value

β (95% CI)

Girls (vs. boys)

Effect on log (DM/DX)

Height (10 cm)

Age (year)

Age or surrogate variable

Results of the linear mixed model with random intercept and random slope covariance structure for age or surrogate variables on log(DM/DX)

|
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contraceptive users and nonusers have not been associated with changes in CYP2D6 phenotype based on
urinary DM/DX ratios.33,35–39 In contrast, DM phenotyping studies during pregnancy have detected changes
in CYP2D6 activity,41,42 with the urinary DM/DX ratio
reported to be 25.6%, 34.8%, and 47.8% lower at 14–18,
24–28, and 36–40 weeks gestation, respectively, indicating increased CYP2D6 activity compared to the postpartum period.42 The mechanism of CYP2D6 regulation
during pregnancy appears to involve complex interactions among retinoic acid, small heterodimer partner,
and Kruppel-like factor-9, and continues to be elucidated,43–45 but little is known concerning analogous regulatory factors during puberty.
Somewhat surprising was the difference in log(DM/DX)
values between patients with ADHD and similarly aged
children and adolescents without a diagnosis of ADHD. We
are not aware of any influence of ADHD itself on CYP2D6
activity, but one notable difference between patients with
ADHD and non-ADHD patients in our study was the use
of medications to manage the disorder, such as stimulants
(amphetamine and methylphenidate formulations) and
α-agonists (clonidine and guanfacine). In fact, it appears
that the “ADHD effect” is driven entirely by concurrent
administration of amphetamine formulations, which was
reported for 118 of the 1105 total study visits (35.6% of
patients with ADHD at visit 1, declining to 18.4% at visit
7). Amphetamine has been reported to be an inhibitor of
CYP2D6 in vitro, with a Ki value of 26.5 uM in human
liver microsomes, greater than 100-fold less potent than
the di-methoxy analogue, MMDA—a known CYP2D6 inhibitor with a Ki of 0.17 μM under the same experimental
conditions.46 However, a review of stimulant drug–drug
interactions found little evidence of clinical interactions
between amphetamines and CYP2D6 substrates, albeit
there few reports to assess,47 and amphetamines are not
included in the FDA lists of CYP2D6 inhibitors (https://
www.fda.gov/drugs/d rug-i ntera ction s-l abeli ng/drug-
development-and-drug-interactions-table-substrates-inhib
itors-and-inducers; https://www.fda.gov/regulatory-infor
mation/search-fda-guidance-documents/clinical-drug-
interaction-studies-cytochrome-p450-enzyme-and-trans
porter-mediated-drug-interactions; both accessed June
11, 2022). Among patients with ADHD, treatment with
amphetamine formulations was associated with lower
urinary pH values (p = 0.008), whereas no differences in
urinary pH were observed with use of methylphenidate
or α-agonists. Thus, we cannot exclude the possibility that
the ADHD effect is a false-positive result due to amphetamine effects on urinary pH, with subsequent effects on
DM/DX values.
The primary conclusion of this study is that CYP2D6
genotype remains the single, largest determinant of
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variability of CYP2D6 enzyme activity during adolescence, and incorporation of genotype-based dosing
guidelines should be considered for CYP2D6 substrates,
especially given the prevalence of use of these agents
in this pediatric age group. To improve the development
of medication dosing guidelines for children, ontogeny
functions for drug metabolizing enzymes have been incorporated into several physiologically-based pharmacokinetic platforms, and their application to simulating
dose–exposure relationships in pediatric patients at a
population level is gaining acceptance among researchers, pharmaceutical companies, and regulatory agencies.48–50 Implementation of precision therapeutics at
the level of individual patients requires knowledge of
patient genotype, but also requires knowledge of the effect of CYP2D6 genotype on the dose–exposure relationship for a given drug. The reality is that genotype, per se,
is not sufficient to truly individualize dosing as three- to
five-fold differences in exposure can be observed within
a CYP2D6 AS group, as demonstrated for atomoxetine.16 A challenge for the future remains to build on,
and extend, the accumulating database describing the
relative contribution of ontogeny and genetic variation
to observed variability in drug disposition and response
across the continuum from birth to adulthood.
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